CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $153,237 | -25.2% | 3,376 | -7.5% | 0.02% | -18.5% |
| Q2 2023 | $204,799 | +16.9% | 3,648 | -5.8% | 0.03% | +12.5% |
| Q1 2023 | $175,221 | +10.2% | 3,874 | -1.0% | 0.02% | +4.3% |
| Q4 2022 | $159,023 | -37.9% | 3,912 | 0.0% | 0.02% | -45.2% |
| Q3 2022 | $256,000 | -5.5% | 3,912 | +133.6% | 0.04% | -8.7% |
| Q2 2022 | $271,000 | +7.5% | 1,675 | -58.3% | 0.05% | +21.1% |
| Q1 2022 | $252,000 | +27.3% | 4,021 | +53.8% | 0.04% | +26.7% |
| Q4 2021 | $198,000 | +10.0% | 2,614 | +63.0% | 0.03% | -3.2% |
| Q3 2021 | $180,000 | -33.6% | 1,604 | -4.2% | 0.03% | -32.6% |
| Q2 2021 | $271,000 | +71.5% | 1,675 | +29.1% | 0.05% | +64.3% |
| Q1 2021 | $158,000 | +7.5% | 1,297 | +35.4% | 0.03% | 0.0% |
| Q4 2020 | $147,000 | +81.5% | 958 | -1.4% | 0.03% | +64.7% |
| Q3 2020 | $81,000 | +80.0% | 972 | +58.3% | 0.02% | +70.0% |
| Q2 2020 | $45,000 | – | 614 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |